

3rd Annual Jefferson Liver Disease Symposium

Saturday, April 1, 2017

At the conclusion of this CME activity, participants will be able to:

- Identify and appraise the new and emerging innovative drug treatments for the management of chronic hepatitis C infection and appreciate further advancements in the field over the past 12 months.
- Develop an understanding as to when to initiate antiviral prophylaxis in special populations of patients with chronic hepatitis B infection or prior exposure to HBV (e.g. pregnant women and hepatitis B core Ab (+) patients undergoing immunosuppressive therapies).
- Discuss and analyze the novel approaches to treating patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic hepatitis.
- Describe the epidemiology, disease manifestations and treatment of hepatitis E infection.
- Appreciate the new name and new FDA-approved therapy for the cholestatic liver disease, Primary Biliary Cholangitis (PBC).
- Review the classification and approach to management in patients with genetic iron overload.
- Describe the role of the hepatology mid-level provider in a busy academic transplant hepatology practice, especially highlighting their value in patient care coordination.
- Appreciate the spectrum of disease of the clinical entity “acute-on-chronic liver failure”.
- Expand on the various strategies to expand the donor pool for liver transplantation and, in understand what is meant by DCD, DBD, ECD and PHS-high risk donors.
- List a differential diagnosis of benign solid liver masses and understand how to distinguish these based on cross-sectional liver imaging techniques.
- Acknowledge the role of telemedicine in the practice of transplant hepatology.
- Assess their individual practice in light of the information and discussions during the course, and identify specific strategies to implement as part of a continuing improvement process for their practices.